SLDB

MKT CAP:$620M

Solid Biosciences Inc.

Market Cap

$620M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$8.26+$2.81 (+51.47%)

Apr 23, 2026

Company Details

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functi...

CEO

Alexander G. Cumbo

IPO Date

Jan 26, 2018

Website

www.solidbio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$174M

EPS (Diluted)

-$2.02

Free Cash Flow

-$157M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 19, 2026

$0EPS -$1.99

Q4 2025

Mar 19, 2026

$0EPS -$0.53

Q3 2025

Nov 3, 2025

$0EPS -$0.48

Q2 2025

Aug 12, 2025

$0EPS -$0.42

Q1 2025

May 15, 2025

$0EPS -$0.59

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$2M	$2M	-$25M
Q2 22	$6M	$6M	-$25M
Q3 22	$0	$0	-$21M
Q4 22	$0	$0	-$35M
Q1 23	$0	$0	-$32M
Q2 23	$0	$0	-$27M
Q3 23	$0	$0	-$23M
Q4 23	$0	$0	-$22M
Q1 24	$0	-$327.0K	-$27M
Q2 24	$0	$0	-$28M
Q3 24	$0	$0	-$35M
Q4 24	$0	$0	-$40M
Q1 25	$0	-$407.0K	-$40M
Q2 25	$0	-$386.0K	-$42M
Q3 25	$0	$0	-$48M
Q4 25	$0	-$467.0K	-$49M

Valuation

Quarter	P/S	P/E
Q1 22	11.2x	—
Q2 22	4.5x	—
Q3 22	5.3x	—
Q4 22	14.5x	—
Q1 23	15.2x	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$27M	-$27M
Q2 22	-$16M	-$17M
Q3 22	-$20M	-$21M
Q4 22	-$34M	-$35M
Q1 23	-$28M	-$29M
Q2 23	-$27M	-$28M
Q3 23	-$18M	-$18M
Q4 23	-$21M	-$21M
Q1 24	-$25M	-$25M
Q2 24	-$21M	-$22M
Q3 24	-$24M	-$24M
Q4 24	-$30M	-$30M
Q1 25	-$32M	-$32M
Q2 25	-$37M	-$38M
Q3 25	-$33M	-$34M
Q4 25	-$54M	-$54M

Capital Expenditures

Quarter	CapEx
Q1 22	$184.0K
Q2 22	$1M
Q3 22	$839.0K
Q4 22	$856.0K
Q1 23	$506.0K
Q2 23	$536.0K
Q3 23	$383.0K
Q4 23	$90.0K
Q1 24	$149.0K
Q2 24	$286.0K
Q3 24	$15.0K
Q4 24	$204.0K
Q1 25	$126.0K
Q2 25	$377.0K
Q3 25	$85.0K
Q4 25	$565.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	-42.3%	+35.0%
Q2 22	+71.6%	+41.6%
Q3 22	-100.0%	-2.0%
Q4 22	-100.0%	+58.5%
Q1 23	-100.0%	+17.3%
Q2 23	-100.0%	-14.9%
Q3 23	—	+9.4%
Q4 23	—	-35.6%
Q1 24	—	-16.1%
Q2 24	—	+3.5%
Q3 24	—	+52.2%
Q4 24	—	+79.2%
Q1 25	—	+49.1%
Q2 25	—	+50.0%
Q3 25	—	+36.6%
Q4 25	—	+23.8%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$3M	135.7%
Q2 22	$2M	29.4%
Q3 22	$2M	—
Q4 22	$2M	—
Q1 23	$2M	—
Q2 23	$2M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$2M	—
Q2 24	$2M	—
Q3 24	$3M	—
Q4 24	$4M	—
Q1 25	$3M	—
Q2 25	$3M	—
Q3 25	$4M	—
Q4 25	$7M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$20M	$7M	—
Q2 22	$23M	$7M	—
Q3 22	$14M	$7M	—
Q4 22	$21M	$8M	—
Q1 23	$25M	$7M	—
Q2 23	$20M	$7M	—
Q3 23	$17M	$6M	—
Q4 23	$15M	$7M	—
Q1 24	$19M	$8M	—
Q2 24	$19M	$8M	—
Q3 24	$27M	$8M	—
Q4 24	$31M	$9M	—
Q1 25	$31M	$9M	—
Q2 25	$32M	$9M	—
Q3 25	$39M	$9M	—
Q4 25	$38M	—	$11M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$130M	$50M	$180M
Q2 22	$54M	$109M	$163M
Q3 22	$49M	$93M	$142M
Q4 22	$155M	$58M	$214M
Q1 23	$165M	$21M	$186M
Q2 23	$92M	$69M	$160M
Q3 23	$49M	$94M	$143M
Q4 23	$74M	$50M	$124M
Q1 24	$118M	$88M	$206M
Q2 24	$96M	$94M	$190M
Q3 24	$64M	$107M	$171M
Q4 24	$80M	$69M	$149M
Q1 25	$211M	$96M	$307M
Q2 25	$139M	$129M	$268M
Q3 25	$61M	$175M	$236M
Q4 25	$61M	$128M	$189M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	8M	+0.3%	+26.1%
Q2 22	8M	+0.2%	+0.5%
Q3 22	8M	+0.1%	+0.7%
Q4 22	8M	+6.5%	+7.1%
Q1 23	20M	+143.9%	+160.7%
Q2 23	20M	+0.5%	+161.3%
Q3 23	20M	+2.0%	+166.3%
Q4 23	29M	+44.7%	+261.7%
Q1 24	38M	+31.5%	+95.0%
Q2 24	41M	+7.3%	+108.2%
Q3 24	41M	+1.2%	+106.6%
Q4 24	54M	+29.3%	+84.6%
Q1 25	66M	+23.8%	+73.9%
Q2 25	94M	+41.9%	+130.0%
Q3 25	94M	+0.3%	+127.8%
Q4 25	95M	+0.3%	+76.8%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$18.5K	104
Q2 22	$59.3K	104
Q3 22	$0	104
Q4 22	$0	87
Q1 23	$0	87
Q2 23	$0	87
Q3 23	$0	87
Q4 23	$0	88
Q1 24	$0	88
Q2 24	$0	88
Q3 24	$0	88
Q4 24	$0	100
Q1 25	$0	100
Q2 25	$0	100
Q3 25	$0	100
Q4 25	$0	40K

Revenue / Employee